Skip to main content
Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
5.60
-0.21 (-3.61%)
At close: Mar 9, 2026, 4:00 PM EDT
5.64
+0.04 (0.71%)
After-hours: Mar 9, 2026, 7:59 PM EDT

Xeris Biopharma Holdings Revenue

In the year 2025, Xeris Biopharma Holdings had annual revenue of $291.85M with 43.72% growth. Xeris Biopharma Holdings had revenue of $85.81M in the quarter ending December 31, 2025, with 42.78% growth.

Revenue (ttm)
$291.85M
Revenue Growth
+43.72%
P/S Ratio
3.31
Revenue / Employee
$740,723
Employees
394
Market Cap
965.62M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025291.85M88.78M43.72%
Dec 31, 2024203.07M39.16M23.89%
Dec 31, 2023163.91M53.67M48.68%
Dec 31, 2022110.25M60.66M122.32%
Dec 31, 202149.59M29.16M142.67%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Pharming Group 362.27M
Geron 183.88M
UroGen Pharma 109.79M
AbCellera Biologics 75.13M
Aktis Oncology 5.56M
Inhibrx Biosciences 1.40M
Compass Therapeutics 850.00K
Revenue Rankings

XERS News

More News